Sin conexión a internet: se muestra la versión guardada de la página.

Agios Pharm

USUSD
← Al Screener

Agios Pharm (LSE:0HB0) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
agios.com
Relaciones con los Inversores
investor.agios.com/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Sede Central
Cambridge, United States
Consejero Delegado
Brian M. Goff
Empleados
539
Fundada
2008
Acciones en Circulación
59.7 M a 2026-07-24
Capital Flotante
50.02 M
Capitalización Bursátil
2 mil M USD
Insiders
1.07%
Inversores Institucionales
112.31%
Industria (SIC)
Pharmaceutical Preparations
ISIN
US00847X1046
LEI
529900ONJHY8EOGYT555
FCF
−365 M USD
Deuda
0
Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
Descripción

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksAGIO principalUSD31.92 +0.41%acciones ordinarias
LSE London Stock Exchange0HB0 IOBUSD33.1105 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo
anuncio

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Blackrock Inc.10.81%6.46 M2026-06-30
Farallon Capital Managem…9.91%5.92 M2026-06-30
State Street Corporation5.92%3.53 M2026-06-30
Lynx1 Capital Management…5.71%3.41 M2026-06-30
Shaw D.E. & Co., Inc.5.2%3.11 M2026-06-30
Vanguard Portfolio Manag…4.85%2.9 M2026-06-30
Vanguard Capital Managem…4.49%2.68 M2026-06-30
Armistice Capital, LLC4.02%2.4 M2026-06-30
Erste Asset Management G…3.61%2.15 M2026-06-30
SPDR SERIES TRUST-State…3.54%2.11 M2026-08-31
Nomura Asset Management…3.54%2.11 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.16%1.89 M2026-06-30
iShares Trust-iShares Ru…2.52%1.51 M2026-07-31
VANGUARD INDEX FUNDS-Van…2.28%1.36 M2026-06-30
Delaware Group Equity Fu…1.92%1.14 M2026-05-31
VANGUARD INDEX FUNDS-Van…1.32%788 6552026-06-30
VANGUARD INDEX FUNDS-Van…1.15%683 9902026-06-30
Fidelity Salem Street Tr…1.08%646 3182026-07-31
Fidelity Rutland Square…0.88%526 1212026-07-31
iShares Trust-iShares Ru…0.86%511 9942026-07-31
FOUSE JACQUALYN A. (Dire…≈0.26%154 1562026-06-18
GHEUENS SARAH (Officer)≈0.09%54 6452026-08-04
SCADDEN DAVID T. (Direct…≈0.03%20 4192026-06-18
HO MAYKIN (Director)≈0.03%19 8482026-06-18
BALLAL RAHUL D. (Directo…≈0.03%15 2302026-06-18
SMITH CYNTHIA (Director)≈0.03%15 2302026-06-18
FOSTER-CHEEK KAYE I (Dir…≈0.02%12 4842026-06-18
ADAMS CATHERINE OWEN (Di…≈0.02%10 8652026-06-18
CAPELLO JEFFREY D (Direc…≈0.02%10 8652026-06-18
BACKSTROM JAY T (Directo…≈0%1 4472026-07-08